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Although poly(ADP-ribose) polymerase (PARP) in-
hibitors are active in homologous recombination
(HR)-deficient cancers, their utility is limited by ac-
quired resistance after restoration of HR. Here, we
report that dinaciclib, an inhibitor of cyclin-depen-
dent kinases (CDKs) 1, 2, 5, and 9, additionally has
potent activity against CDK12, a transcriptional regu-
lator of HR. In BRCA-mutated triple-negative breast
cancer (TNBC) cells and patient-derived xenografts
(PDXs), dinaciclib ablates restored HR and reverses
PARP inhibitor resistance. Additionally, we show
that de novo resistance to PARP inhibition in
BRCA1-mutated cell lines and a PDX derived from
a PARP-inhibitor-naive BRCA1 carrier is mediated
by residual HR and is reversed by CDK12 inhibi-
tion. Finally, dinaciclib augments the degree of
response in a PARP-inhibitor-sensitive model, con-
verting tumor growth inhibition to durable regres-
sion. These results highlight the significance of HR
disruption as a therapeutic strategy and supportCell Repor
This is an open access article under the CC BY-Nthe broad use of combined CDK12 and PARP inhibi-
tion in TNBC.INTRODUCTION
Poly(ADP-ribose) polymerase (PARP) inhibition has emerged as
a compelling strategy for BRCA-deficient or otherwise homolo-
gous recombination (HR)-repair-deficient cancers (Scott et al.,
2015). However, the broad utility of these drugs has been limited
by their lack of activity in HR-proficient cancers, as well as ac-
quired resistance of initially responding tumors, often mediated
by restoration of HR (Bouwman and Jonkers, 2014). Additionally,
a proportion of BRCA-mutated cancers display de novo (pri-
mary) resistance, potentially mediated by hypomorphic isoforms
of BRCA1 (Hill et al., 2014), tumor heterozygosity (King et al.,
2007), or preexisting alterations in the DNA damage response
that may confer residual HR activity (Bouwman et al., 2010).
These challenges have prompted interest in combining
PARP inhibitors with agents capable of disrupting HR in cancer
cells as an approach to sensitize BRCA wild-type cancers to
PARP inhibition, and also to overcome de novo and acquired
resistance in BRCA-mutated cancers. Because complex mech-
anisms of HR restoration confer resistance to PARP inhibitors ints 17, 2367–2381, November 22, 2016 ª 2016 The Author(s). 2367
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
BRCA-mutated cells, simultaneous suppression of multiple HR
genes together with PARP inhibition may be a preferred strategy
for resensitizing resistant cells to these agents. In this regard,
cyclin-dependent kinase (CDK) 12, an RNA polymerase II C-ter-
minal domain (CTD) kinase, has recently been identified as
an essential regulator for the transcription of various DNA dam-
age response (DDR) and DNA repair genes, particularly those
involved in the HR and Fanconi anemia (FA) pathways (Bartko-
wiak et al., 2010; Blazek et al., 2011; Liang et al., 2015). Somatic
inactivating mutations in CDK12 have been observed in a subset
of epithelial ovarian carcinomas, resulting in compromised HR
(Joshi et al., 2014). Furthermore, short hairpin RNA (shRNA)-
mediated depletion of CDK12, or its cyclin K binding partner,
from BRCA and CDK12 wild-type ovarian cancer or other trans-
formed cell lines has been shown to suppress HR gene expres-
sion and sensitize cells to cisplatin-induced interstrand cross-
links and PARP inhibition (Bajrami et al., 2014; Blazek et al.,
2011; Joshi et al., 2014).
These observations have led to interest in the development of
pharmacological inhibitors of CDK12 to act as sensitizers to
PARP inhibitors, as well as to standard DNA-damaging agents.
Here, we show that dinaciclib, a known inhibitor of CDKs 1, 2,
5, and 9 (Parry et al., 2010) that has produced documented re-
sponses in breast cancer (Mita et al., 2014), has previously unre-
ported potent activity against CDK12. We studied dinaciclib as a
CDK12 inhibitor in models of triple-negative breast cancer
(TNBC), an aggressive breast cancer subset associated with
poor outcome and absence of definedmolecular targets. Dinaci-
clib reduces HR gene expression in BRCA wild-type TNBC cells
and sensitizes these cells to PARP inhibition. We have further
investigated the activity of dinaciclib in concert with PARP inhibi-
tion in BRCA-mutated TNBC cell lines and patient-derived xeno-
graft (PDX) models, and demonstrate reversal of de novo and
acquired PARP inhibitor resistance. Finally, in a BRCA-mutated
model in which long-term tumor growth control is achieved by
PARP inhibitor monotherapy, the addition of dinaciclib converts
the outcome to deep and prolonged tumor regression. Collec-
tively, these data support the combination of dinaciclib with
PARP inhibition in both BRCA wild-type and mutant TNBCs.
RESULTS
Dinaciclib Inhibits CDK12 with Greater Potency Than
Other Known Transcriptional CDK Inhibitors
To identify potential inhibitors of CDK12, we made use of
its recently elucidated crystal structure. Although the kinase
domain of CDK12 shares significant primary sequence homol-
ogy with CDK9, a panel of small-molecule CDK9 inhibitors was
previously shown to have substantially reduced potency against
CDK12 in in vitro biochemical assays (Bo¨sken et al., 2014). To
further interrogate this result, we aligned the CDK12 crystal
structure 4NST with the CDK9 crystal structure 3BLQ (Baumli
et al., 2008). Although the two kinases share extensive tertiary
structural homology (root-mean-square deviation [RMSD] =
0.83 A˚; Figure 1A), inspection of secondary structure elements
demonstrated a variance in the C-terminal portion of each kinase
domain (Figures 1B and S1A). CDKs that regulate transcriptional
elongation have a unique extension helix that lies C-terminal to2368 Cell Reports 17, 2367–2381, November 22, 2016the canonical CDK kinase domain. In CDK12, this extension helix
interacts with the ATP binding site and is initiated by a DCHEL
motif beginning at amino acid 1038. The interaction of the C-ter-
minal extension helix with the nucleotide binding site of CDK12 is
mediated by the H1040 and E1041 residues, and loss of the helix
severely disrupts activity of the kinase (Bo¨sken et al., 2014).
CDK9 shares a similar C-terminal extension helix, but does not
share the initiating 1038DCHEL motif (Figure 1B). Because this
structural variation occurs in close proximity to the site of binding
for small-molecule inhibitors of CDK9, we hypothesized that it
may be responsible for the lack of shared specificity with
CDK12. In silicomodeling of flavopiridol, a well-described potent
CDK9 inhibitor, into the ATP binding site of CDK12 revealed a
significant steric clash between the benzene ring of bound flavo-
piridol and the H1040 residue of the DCHEL motif of CDK12. To
determine whether this occlusion was a shared feature of other
compounds that tightly bind CDK9, we modeled dinaciclib, a
CDK9 inhibitor that had not been tested against CDK12, into
the CDK12 ATP binding site. In contrast with flavopiridol, there
does not appear to be steric hindrance between the CDK12
H1040 aromatic ring and the pyridine-N-oxide ring of dinaciclib
(Figure 1B).
We predicted that this favorable interaction would afford
potent CDK12 inhibitory activity to dinaciclib. The addition of
103 or 1,0003 concentration of dinaciclib to 0.2 mM cyclin
K-CDK12 or cyclin T-CDK9 holoenzyme complexes reduced
CDK12 activity by approximately 20-fold and CDK9 activity by
12- to 25-fold (Figure 1C). Compared with previously reported
results of similar assays using other CDK9 inhibitors (Bo¨sken
et al., 2014), dinaciclib demonstrates strong inhibition of
CDK12 kinase activity. Concentration series were then per-
formed to determine half-maximal inhibitory concentration
(IC50) values against CDK12 and other CDK familymembers (Fig-
ures 1D and S1B). Whereas flavopiridol had only modest activity
against CDK12 with potency compared with CDK9 reduced by
more than 10-fold (Bo¨sken et al., 2014), dinaciclib demonstrated
robust inhibitory activity against both kinases, with IC50 in the
40–60 nM range, making it the most potent known inhibitor of
CDK12. Furthermore, mutation of the H1040 site to glycine, or
mutation of either the DCHEL motif or the adjacent polybasic
region to alanine conferred sensitivity of CDK12 to flavopiridol,
consistent with the predictions of structural modeling. In
contrast, these three CDK12 mutations had no effect on the
IC50 of dinaciclib (Figure 1D).
Dinaciclib Displays Hallmarks of CDK12 Inhibition in
BRCA Wild-Type TNBC Cells
We next characterized the transcriptional effects of dinaciclib
treatment on TNBC cells. Eukaryotic gene transcription is regu-
lated by a coordinated sequence of phosphorylation events
along the CTD of RNA polymerase II. CDK9 is recruited to the
50 ends of gene bodies, where it primarily phosphorylates
CTD-Ser5, releasing the assembled transcription complex from
promoter-proximal pausing and initiating transcription (Eick
and Geyer, 2013; Ghamari et al., 2013). CDK12 is predominantly
associated with the 30 ends of genes, where it has been shown to
coordinate transcript elongation and processing largely by phos-
phorylation of CTD-Ser2 (Bartkowiak et al., 2010; Blazek et al.,
Figure 1. Dinaciclib Is a Potent Inhibitor of CDK12 in Addition to CDK9
(A) Tertiary structural alignment of CDK9 and CDK12.
(B) Sequence corresponding to the variance in the C-terminal extension helix of the kinase domains of CDK12 and CDK9 (see also Figure S1), as well as structural
modeling of the orientations of flavopiridol and dinaciclib in relation to H1040 and E1041 of the CDK12 ATP binding site. The benzene ring of flavopiridol shows a
steric clash with H1040 of CDK12, whereas the pyridine-N-oxide ring of dinaciclib overlaps the aromatic H1040 side chain, resulting in a possible stacking of the
aromatic ring systems that stabilizes the interaction and contributes to binding specificity.
(C) In vitro kinase assays using pS7-CTD[3] as substrate and 0.2 mM cyclin T-CDK9 and cyclin K-CDK12 holoenzyme complexes alone or with 103 or 1,0003
dinaciclib.
(D) Concentration series of dinaciclib and flavopiridol for cyclin T1-CDK9 and cyclin K-CDK12 at 0.2 mM kinase concentration. The IC50 values against CDK9 and
CDK12 are comparable for dinaciclib, but disparate for flavopiridol. Introduction of the indicated mutations sensitizes CDK12 to flavopiridol. All data are reported
as the mean ± SD from three independent experiments.
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2011; Eick and Geyer, 2013). Treatment of MDA-MB-231 cells
with low nanomolar concentrations of dinaciclib for 6 hr resulted
in concentration-dependent reduction in phospho-CTD levels,
with greater effects on Ser2 compared with Ser5 phosphoryla-
tion (Figure 2A).
Whereas CDK9-mediated phosphorylation of RNA polymer-
ase II occurs globally across transcripts (Garriga and Gran˜a,
2004), CDK12 predominantly associates with the 30 ends of
genes involved with DNA damage and repair (Blazek et al.,
2011). Gene expression analysis of RNA collected from MDA-
MB-231 cells after 12 hr of dinaciclib exposure showed a signif-
icant reduction in expression of only a limited number of genes,
in contrast with the global transcriptional repression that has
been reportedwith potent CDK9 inhibitors (Lam et al., 2001) (Fig-
ure 2B). Pathway analysis revealed that the differentially ex-
pressed genes were significantly enriched for those involved in
HR repair and DNA damage-sensing (Figures 2C and S2A),
with representation from multiple genes previously reported to
be repressed by disruption of CDK12 activity (Blazek et al.,
2011) (Figure 2D). We confirmed these results via qPCR using
primers for BRCA1 and RAD51 (Figure 2E). Consequently, the
expression of multiple proteins involved in HR was decreased
in dinaciclib-treated cells, demonstrated in both concentration-
and time-dependent experiments, with substantial reduction of
these proteins by 24 hr (Figures 2F and 2G). Importantly, the tran-
scriptional effects of dinaciclib could not be attributed to a block
in cell cycle progression, because we observed only minimal cell
cycle perturbations in asynchronous or hydroxyurea-synchro-
nized cells (Figures 2H and S2B). Taken together, these data
suggest that dinaciclib acts primarily as a transcriptional CDK in-
hibitor in TNBC cells, and that the transcriptional consequences
of dinaciclib exposure are predominantly associated with its in-
hibition of CDK12.
Dinaciclib Compromises HR Repair and Sensitizes
BRCA Wild-Type TNBC Cells to PARP Inhibition
We reasoned that the transcriptional effects of dinaciclib that we
observed would severely impair HR, as reported in multiple
myeloma cells (Alagpulinsa et al., 2016). To test this prediction,
we assessed functional metrics of HR in BRCA wild-type TNBC
cells. Irradiated MDA-MB-231 cells pretreated with dinaciclib
showed significant concentration-dependent reduction in the
recruitment of BRCA1 and RAD51 to sites of double-strand
DNA breaks (Figures 3A and 3B). To directly measure HR, we uti-
lized U2OS cells with stable integration of the DR-GFP reporter.
Transfection of the I-SceI restriction enzyme resulted in 13.3%
and 3.6% GFP-positive cells following vehicle or dinaciclib treat-
ment, respectively (Figures 3C andS3A). The profound disruption
ofHRsuggested thatdinaciclibcould sensitizeHR-proficient cells
toPARP inhibition.We found thatdinaciclib treatment sensitizeda
panel ofBRCAwild-type TNBC cell lines to the PARP inhibitor ve-
liparib (Figures 3DandS3B). In the presence of dinaciclib, the IC50
to veliparib was reduced between 2.5- and 12.5-fold (Table S1).
Effects of Dinaciclib in TNBC Cells Are Phenocopied by
CDK12 Knockout
To provide further evidence that the effects of dinaciclib are
mediated by CDK12 inhibition, we utilized CRISPR/Cas9-medi-2370 Cell Reports 17, 2367–2381, November 22, 2016ated knockout of CDK12 in MDA-MB-468 and BT549 cells (Fig-
ure S4A). Knockout of CDK12 caused reduced expression of
BRCA1, BRCA2, and RAD51, which compromised RAD51 focus
formation after g-irradiation, and resulted in substantial sensiti-
zation to veliparib. Importantly, treatment with dinaciclib did
not further sensitize CDK12-depleted cells to veliparib. CDK9
knockout did not reduce HR gene expression (Figure S4A).
Consistent with previously published results, CDK9 knockout
over several days was lethal to TNBC cells (Wang et al., 2015).
We therefore used low concentrations of flavopiridol (Fig-
ure S4B), which reduced phosphorylation of Ser5, but not
Ser2, of the CTD, and we observed no impact on HR gene
expression or RAD51 focus formation after DNA damage.
In contrast with dinaciclib or CDK12 knockout, flavopiridol
did not sensitize TNBC cells to veliparib- or olaparib-mediated
PARP inhibition.
BRCA Mutant TNBC Cells with Acquired PARP Inhibitor
Resistance Are Resensitized to PARP Inhibition by
Dinaciclib
Many mechanisms of acquired PARP inhibitor resistance have
shared a common feature in that they restore RAD51 loading
and rescue HR repair. We hypothesized that the multifocal
disruption of HR resulting from CDK12 inhibition could poten-
tially resensitize BRCA-mutated cells that have developed
resistance to PARP inhibition. We made use of a previously
generated PARP-inhibitor-resistant clone of the BRCA1-
mutated MDA-MB-436 cell line, in which heterozygous mutation
of the TP53BP1 gene and stabilization of a hypomorphic BRCT-
domain-mutated BRCA1 protein results in rescue of DNA end
resection, RAD51 loading, and HR (Johnson et al., 2013). Dinaci-
clib treatment substantially reduced protein levels of both
RAD51 and the hypomorphic BRCA1 mutant protein, as well
as formation of RAD51 foci following irradiation, and resensitized
the resistant cells to PARP inhibition (Figure 3E; Table S1).
To test the ability of dinaciclib to reverse acquired PARP inhib-
itor resistance in vivo, we generated a PDXmodel derived from a
TNBC patient carrying a germline S1970* BRCA2mutation. This
heavily pretreated patient achieved stable disease for approxi-
mately 10 months on combined cisplatin and olaparib followed
by olaparib alone (Balman˜a et al., 2014), before disease progres-
sion. After brief intervening chemotherapy, a biopsy was per-
formed when new hepatic metastases developed, which was
used for establishment of the PDX 12-58 model (Figure 3F) (Tao
et al., 2014). Although targeted sequencing did not demonstrate
evidence of a BRCA2 reversion mutation (Figure S5A), the model
was refractory to cisplatin as well as veliparib (Figures 3G and
3H), requiring animal euthanasia at approximately 40 days for
progressive tumor growth, suggesting alternative mechanisms
governing resistance. However, the combination of dinaciclib
and veliparib resulted in tumor growth inhibition lasting at least
60 days (Figure 3H). End-of-experiment histology revealed no
abnormalities in lung, liver, gastrointestinal (GI) tract, and bone
marrow of combination-treated mice, with similar appearance
of organs harvested from vehicle-treated mice and only modest
staining for gamma-H2AX (g-H2AX) in marrow (Figure S5B).
To further study the selectivity of combination treatment for
transformed cells, we exposed human mammary epithelial cells
Figure 2. Dinaciclib Is a Transcriptional CDK Inhibitor That Reduces Expression of Genes in DNA Damage Response and DNA Repair
Pathways
(A) MDA-MB-231 cells were treated with the indicated concentrations of dinaciclib for 6 hr, demonstrating reduced phosphorylation at the Ser2 and Ser5 sites of
the CTD of RNA polymerase II.
(B) Cells were collected before and after treatment with 10 nM dinaciclib for 12 hr, and changes in transcription were measured using the Affymetrix HG-U133A2
arrays. Analyses were performed in triplicate. Twenty-one percent of genes were significantly downregulated in dinaciclib-treated versus untreated samples
(p < 0.05).
(C) Genes statistically significantly downregulated in response to dinaciclib were analyzed by Ingenuity Pathway Analysis (IPA) software, demonstrating
downregulation of DNA damage response and DNA repair pathways.
(D) Expression of genes in the ‘‘role of BRCA1 in DNA damage response’’ pathway.
(E) Downregulation of expression of BRCA1 and RAD51mRNAs in cells treated with the indicated concentrations of dinaciclib was confirmed utilizing RT-PCR.
(F) Concentration-dependent reduction in expression of BRCA1, BRCA2, RAD51, and FANCD2 in cells treated with dinaciclib for 24 hr.
(G) Time-dependent reduction in expression of BRCA1 and RAD51 in response to dinaciclib.
(H) Cell cycle patterns following dinaciclib exposure demonstrate the absence of G1 arrest in MDA-MB-231 cells (see also Figure S2).
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(HMECs) to olaparib in the absence or presence of dinaciclib
(Figure S5C). In contrast with transformed cells, dinaciclib
improved the viability of HMECs treated with olaparib; this pro-
tective effect was likely due to the much greater degree of G2 ar-
rest observed, which should preclude PARP-inhibitor-mediated
cytotoxicity that typically occurs in S phase.
Characterization ofBRCA1-Mutated TNBCCells with De
Novo PARP Inhibitor Resistance
In addition to acquired PARP inhibitor resistance, there is a high
rate of de novo resistance to PARP inhibition in BRCA-mutated
tumors. To address the utility of CDK12 inhibition in this setting,
we first identified and characterized BRCA-mutated cell lines
with primary PARP inhibitor resistance. Relative PARP inhibitor
sensitivity was determined for a panel of BRCA1-mutated
TNBC cell lines using hormone-receptor-positive and non-trans-
formed breast cell lines as a reference standard for insensitivity
to PARP inhibition. Whereas MDA-MB-436 and HCC1395 dis-
played exquisite sensitivity to PARP inhibition, SUM149 and
HCC1937 were relatively insensitive to PARP inhibitor treatment,
either with veliparib or with olaparib (Figures 4A and S6A). To
determine whether the variability in sensitivity to PARP inhibition
was due to differences in susceptibility to apoptosis, we per-
formed mitochondrial BH3 profiling on the BRCA-mutated cell
lines. No significant differences were observed (Figure S7),
suggesting that resistance to PARP inhibition in SUM149PT
and HCC1937 was not due to an anti-apoptotic phenotype.
In addition to PARP inhibition, HR-deficient tumors are sensi-
tive to the accumulation of DNA interstrand crosslinks (ICLs). To
our surprise, all fourBRCA1-mutated cell lines displayedmarked
sensitivity to cisplatin, regardless of PARP inhibitor sensitivity
(Figure 4A). Furthermore, we observed that treatment with
another DNA crosslinking agent, mitomycin C, resulted in accu-
mulation of chromosomal aberrations in both PARP-inhibitor-
resistant and -sensitiveBRCA1-mutated lines, whereas veliparib
produced chromosomal aberrations in only MDA-MB-436 and
HCC1395 cells (Figure 4B).
While sensitivity to PARP inhibition is associated with defects
in HR, the repair of ICLs requires the activity of multiple DNA
repair pathways, including nucleotide excision repair (NER) andFigure 3. Disruption of HR by Dinaciclib and Sensitization to PARP In
PARP Inhibitor Resistance
(A) Cells were treated with vehicle or 10 nM dinaciclib for 18 hr prior to treatment
RAD51, and g-H2AX focus formation.
(B) Quantification of cells with more than five foci in irradiated cells pretreated w
(C) U2OS DR-GFP cells were transfected with I-SceI in the presence of vehicle or
(p < 0.0001) in the presence of dinaciclib, consistent with direct inhibition of HR
(D) BRCA-proficient TNBC cell lines were treated with veliparib in the absence or
dinaciclib.
(E) An MDA-MB-436 PARP-inhibitor-resistant derivative (MDA-MB-436-RR2) (Jo
dinaciclib, demonstrating reduced IC50 in the presence of dinaciclib (left). Reduce
(middle). MDA-MB-436-RR2 cells were treated with vehicle or dinaciclib at the ind
focus formation 6 hr later (right); p < 0.0001. All data in (B)–(E) are reported as m
(F) Treatment history of the BRCA2 carrier; PDX 12-58 was procured after progr
(G) Mice bearing 12-58 xenografts were treated with vehicle (n = 3) or cisplatin (n
(H) Mice were treated with vehicle (n = 4), veliparib (n = 8), dinaciclib (n = 8), or the
inhibition at day 42 compared with vehicle (p < 0.0001) or monotherapies (p < 0.
*p < 0.01, **p% 0.001, ***p% 0.0001 for experimental value versus control. SD,the Fanconi anemia (FA) pathway, in addition to HR. BRCA1
function is essential for both HR and the FA pathway, and
BRCA1-deficient tumors have been observed to also carry
NER defects. We hypothesized that the BRCA1-mutated cell
lines SUM149PT and HCC1937 may have selectively retained
functional HR while maintaining a defect in NER, as described
for a subset of BRCA1-mutated ovarian carcinomas (Ceccaldi
et al., 2015), or the FA pathway, as in Brca1/ 53BP1/mouse
embryonic fibroblasts (MEFs) that display resistance to PARP
inhibition, but sensitivity to crosslinking agents (Bunting et al.,
2012).
We first assessed NER proficiency in SUM149 and HCC1937,
and failed to detect an NER defect in either cell line (Figure S6B).
We next determined HR and FA pathway proficiency by moni-
toring the recruitment of repair factors immediately downstream
of BRCA1 in both pathways. Recent work has demonstrated
that, in addition to its role in RAD51 loading following end resec-
tion in HR, BRCA1 is required for the removal of stalled replica-
tionmachinery and subsequent recruitment of the FA complex to
the site of crosslinks (Schlacher et al., 2012). We therefore
measured RAD51 and FANCD2 foci formation as surrogate
markers for repair activity downstream of the role of BRCA1 in
the HR and FA pathways, respectively (Figure 4D). Following
PARP inhibitor treatment, a significant increase in RAD51 foci
was observed in SUM149PT and HCC1937, suggesting the
presence of functional HR. Strikingly, none of the BRCA1-
mutated lines displayed recruitment of FANCD2 foci following
cisplatin treatment. These data suggest that similar to the
phenotype observed in MEF genetic studies (Bunting et al.,
2012), human pathogenic mutations in BRCA1may affect sepa-
rate DNA repair pathways to varying extents.
SUM149PT and HCC1937 Cells Require BRCA Proteins
for HR, which Can Be Depleted by Dinaciclib
We next sought to determine pathway components necessary
for the residual HR function of SUM149PT and HCC1937 cells
and whether removal of these factors would result in sensitiza-
tion to PARP inhibition. SUM149PT cells carry a 2288delT muta-
tion in exon 11 of BRCA1, resulting in loss of the full-length
p220 isoform of BRCA1 but detectable levels of a truncatedhibition of BRCA Wild-Type and BRCA-Mutated Cells with Acquired
with 10 Gy g-irradiation (IR). Six hours post-IR, cells were analyzed for BRCA1,
ith vehicle or dinaciclib at the indicated concentrations.
15 nM dinaciclib. The percentage of GFP-positive cells is significantly reduced
repair (see also Figure S3).
presence of dinaciclib, demonstrating reduced IC50 values in the presence of
hnson et al., 2013) was treated with veliparib in the absence or presence of
d expression of the mutant BRCA1 protein and RAD51 in response to dinaciclib
icated concentration for 18 hr, subjected to 10 Gy IR, and assessed for RAD51
ean ± SD for a minimum of three independent experiments.
ession on cisplatin and olaparib (see also Figure S4A).
= 3) on days 1 and 22 (arrows), with tumor volume measured over 36 days.
combination (n = 8). Combination treatment produced significant tumor growth
0001 for both veliparib and dinaciclib).
stable disease. In (G) and (H), data are reported as mean ± SEM.
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Figure 4. Characterization of BRCA1-Mutated TNBC Cell Lines
(A) Panel of indicated cell lines was treated with veliparib or cisplatin over a range of concentrations and viability was assessed after 7 days of treatment.
(B) Cells were treated with vehicle, veliparib, or mitomycin C, and metaphase spreads were prepared; radials quantified in vehicle- and drug-treated cells.
(C) Cells were treated with vehicle, veliparib, or cisplatin and analyzed by immunofluorescence for RAD51 and FANCD2 foci. Graphs show quantification of cells
with more than five foci in vehicle- and drug-treated cells. Data in (A) and (C) are reported as the mean ± SD for a minimum of three independent experiments.BRCA1D672-4095 isoform, BRCA1 D11b, produced from an
in-frame splicing event that removes exon 11 (Hill et al., 2014).
We hypothesized that the BRCA1 D11b isoform, which retains
the C-terminal BRCT domains necessary for RAD51 loading,
may facilitate HR and confer PARP inhibitor resistance. Small
interfering RNA (siRNA)-mediated depletion of BRCA1 D11b
resulted in sensitization of SUM149PT to PARP inhibition (Fig-
ure 5A). Additionally, we observed that siRNA targeting of either
BRCA2 or PALB2 also sensitized SUM149PT to PARP inhibition,
suggesting that the D11 isoform functions in place of p220 in
the BRCA1-PALB2-BRCA2 axis. While the 5382insC BRCA1
mutation in HCC1937 cells ablates expression of both p220
and D11b BRCA1 isoforms, we observed a similar sensitization
to PARP inhibition following siRNA-mediated depletion of both
BRCA2 and PALB2 (Figure 5B).2374 Cell Reports 17, 2367–2381, November 22, 2016Based on these observations, we hypothesized that CDK12 in-
hibitioncould additionally sensitizePARP-inhibitor-naiveBRCA1-
mutated cells to PARP inhibition. Dinaciclib treatment resulted
in a concentration-dependent reduction of BRCA2, RAD51, and
BRCA1 D11b protein levels (Figure 5C), as well as a reduction
in RAD51 foci following g-irradiation (IR) (Figures 5D and 5E).
Additionally, dinaciclib treatment sensitized both SUM149PT
and HCC1937 cells to PARP inhibition (Figure 5F; Table S1).
A 185delAG BRCA1-Mutated PDX Model Demonstrates
Cisplatin Sensitivity and Primary PARP Inhibitor
Resistance with Residual HR Activity That Is Ablated by
Dinaciclib
The significance of residual HR function as a mechanism of
primary resistance to PARP inhibition has not been clarified
Figure 5. BRCA1-Mutated SUM149PT and HCC1937 Cells Are Sensitized to PARP Inhibition by siRNA- or Dinaciclib-Mediated Depletion of
the BRCA1-PALB2-BRCA2 Axis and RAD51
(A) SUM149PT cells were transfected with the indicated siRNAs targeting BRCA1, BRCA2, or PALB2, followed by veliparib treatment at the indicated con-
centrations. Viability was assessed by CellTiter-Glo after seven days.
(B) Similar experiments were performed with HCC1937 cells using siRNAs targeting BRCA2 or PALB2.
(C) Cells were treatedwith vehicle (0 nM) or the indicated concentrations of dinaciclib for 24 hr and nuclear lysates subjected to western blotting with the indicated
antibodies.
(D) Cells were pretreated with vehicle or 10 nM dinaciclib for 18 hr followed by 10 Gy IR. RAD51 and g-H2AX focus formation was assessed by immunofluo-
rescence 6 hr after IR.
(E) Quantification of RAD51 focus formation 6 hr after IR in cells pretreated with vehicle (0 nM) or the indicated concentrations of dinaciclib (p < 0.0001 for di-
naciclib versus vehicle).
(F) Cells were treated with the indicated concentrations of veliparib in the absence or presence of dinaciclib, demonstrating reduced IC50 values in the presence of
dinaciclib.
All data are reported as the mean ± SD for a minimum of three independent experiments.
Cell Reports 17, 2367–2381, November 22, 2016 2375
Figure 6. Generation and Treatment of the PDX 127 Model from a 185delAG BRCA1 Carrier
(A) Treatment history of the BRCA1 carrier; themodel was procured prior to exposure to cisplatin and olaparib or olaparib monotherapy. PD, progressive disease;
PR, partial response.
(B) Mice bearing xenografts were treated with vehicle (n = 4) or cisplatin (n = 6) on the days 1 and 34 (arrows) demonstrating tumor regression in response to
platinum-based treatment.
(C) Mice bearing xenografts were treated with vehicle (n = 8), olaparib (n = 7), dinaciclib (n = 3), or the combination (n = 7). Combination treatment produced
significant tumor growth inhibition compared with vehicle or monotherapies. At day 35, *p = 0.018 for combination versus dinaciclib and **p < 0.0001 for
combination versus olaparib.
(legend continued on next page)
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because of the limited availability of clinical samples. To address
this issue, we established a xenograft model (PDX 127) from a
PARP-inhibitor-naive germline 185delAG BRCA1 carrier pre-
senting with metastatic TNBC (Figure 6A). The patient received
cisplatin and olaparib in combination. After experiencing a partial
response (PR;60% tumor regression) at a dosage of 60 mg/m2
cisplatin and50mg twice-daily olaparib, the patient’s coursewas
complicated by cisplatin-associated peripheral neuropathy,
prompting a transition to 400 mg twice-daily olaparib monother-
apy, onwhich thepatient experienced rapiddisease progression.
Based on the observation that the patient’s PR had occurred on a
suboptimal dose of olaparib, we hypothesized that her disease
may have possessed a platinum-sensitive/PARP-inhibitor-resis-
tant phenotype similar toSUM149PTandHCC1937.Because the
biopsy utilized for generation of the PDX model was procured
prior to receiving cisplatin and olaparib in combination, we
were able to address this question in vivo. Cisplatin treatment
of PDX 127 resulted in tumor regression (Figure 6B), whereas ola-
parib monotherapy demonstrated minimal tumor growth inhibi-
tion (Figure 6C). Whole exome sequencing of the PDX 127model
ruled outBRCA1 reversionmutation as a cause of PARP inhibitor
resistance (Figure S5A). Tumor samples taken from vehicle- and
olaparib-treated PDX 127-bearing mice demonstrated the for-
mation of RAD51 foci following olaparib treatment, supporting
our hypothesis that preservation of HR function had resulted in
PARP inhibitor resistance (Figure 6D).
We next sought to determine whether the combination of dina-
ciclib and olaparib could be extended to this model of primary
PARP inhibitor resistance. Treatment with dinaciclib resulted in
reduced HR gene mRNA and protein expression (Figures 6E
and 6F) in the absence of evidence of cycle arrest (Figure S5D);
as a result, the formation of RAD51 foci in response to olaparib
treatment was significantly suppressed in the combination-
treated mice. Tumors treated with the combination also dis-
played significantly greater induction of g-H2AX foci compared
with those treated with olaparib or dinaciclib alone (Figure 6D).
These effects translated to prolonged disease stabilization in
mice treated with the combination (Figure 6C). These results pro-
vide evidence for the role of residual HR as amechanism of resis-
tance in PARP-inhibitor-naive BRCA1mutant human tumors and
suggest that combining a CDK12 inhibitor with a PARP inhibitor
may be an effective treatment strategy in this setting.
Activity of Combined CDK12 and PARP Inhibition in a
Model with Initial PARP Inhibitor Sensitivity
AlthoughmanyBRCA1/2-mutated tumors display initial sensitivity
to PARP inhibition, treatment in the metastatic setting is not cura-
tive, and clinical benefit is manifested by transient and incomplete(D) Mice bearing xenografts were treated with vehicle, olaparib, dinaciclib, or the c
subjected to immunofluorescence for RAD51 and g-H2AX foci. (Right) Quantifica
with more than five RAD51 foci. For g-H2AX foci, p = 0.103, *p = 0.013, and p =
p < 0.0001 and **p < 0.0076 for dinaciclib or olaparib versus the combination, resp
and p = 0.74 (non-significant [NS]) for control versus dinaciclib, olaparib, or the c
versus the combination, respectively.
All data in (B)–(D) are reported as mean ± SEM.
(E) Tumor RNA frommice in (D) treated with vehicle or dinaciclib (n = 3/group) was
dinaciclib in both cases. Data are reported as the mean ± SD.
(F) Tumor lysates from mice in (D) treated with vehicle or dinaciclib were subjecttumor regressions or sustained stable disease.We established an
additionalPDXmodel (11-26) fromapatientwithearly-stageTNBC
harboring a somaticBRCA1R1443*mutation. Consistent with HR
deficiency, although the PDX model expressed RAD51, foci were
notobservedafter short-termexposure toPARP inhibition (Figures
7A and 7B). As expected, dinaciclib reduced RAD51 expression
(Figure 7B) not attributable to cell cycle arrest (Figure S5D).
PARP inhibitor monotherapy produced stable disease over a
prolonged 156-day time course, although palpable primary tu-
mors were detectable for the duration of the experiment. The
addition of dinaciclib to veliparib resulted in substantial and du-
rable tumor regression (Figures 7C and 7D).
Immunohistochemistry performed on tumors harvested at
the end of the experiment demonstrated viable cell populations
in vehicle- and monotherapy-treated tumors (Figure 7E). In
contrast, bland fibrous tissue predominated in combination-
treated tumors; small nests of tumor cells were present, which
displayed expression of g-H2AX, consistent with the induction
of persistent DNA damage (Figures 7E and 7F). Finally, histolog-
ical analysesof liver, lung,GI tract, andbonemarrowharvestedat
the end of experiment from combination-treated mice revealed
no abnormalities, with only minimal g-H2AX staining, indicating
that the combination of dinaciclib and veliparib was tolerable to
normal tissues over a prolonged treatment course (Figure S5B).
These data suggest that the addition of dinaciclib to PARP inhibi-
tion can augment the quality and degree of response, even in a
tumor initially susceptible to PARP inhibitor monotherapy.
DISCUSSION
The development of PARP inhibitor resistance in BRCA-mutated
cancers is a pressing clinical problem. Restoration of HR plays a
major role in acquired resistance and may occur by varied and
complex mechanisms, highlighting the need for a therapeutic
strategy that can be broadly applied across patients with tumors
resistant to PARP inhibitors. Here, we demonstrate that the
combination of CDK12 and PARP inhibition represents a viable
approach for reversing such resistance.
In the MDA-MB-436 BRCT domain BRCA1mutant derivatives
with acquired PARP inhibitor resistance, RAD51 loading is facil-
itated by an HSP90-stabilized splice variant mutant BRCA1
(Johnson et al., 2013). Because transcription of the BRCA1
splice variant is driven by the intact BRCA1 promoter, inhibition
of CDK12 is expected to reduce its expression. Dinaciclib abla-
ted expression of themutant protein, inhibited HR, and re-estab-
lished PARP inhibitor sensitivity.
Themultiple components of theHRpathway that are transcrip-
tionally downregulated by CDK12 inhibition suggest that thisombination (n = 6/group). (Left) After 15 days, mice were sacrificed and tumors
tion of cells with more than five g-H2AX foci, as well as g-H2AX-positive cells
0.005 for control versus dinaciclib, olaparib, or the combination, respectively.
ectively. For RAD51 quantification in g-H2AX-positive cells, p = 0.69, p = 0.04,
ombination, respectively. p = 0.158 and **p = 0.0035 for dinaciclib or olaparib
subjected to RT-PCR for BRCA1 and RAD51. **p = 0.000068 for vehicle versus
ed to western blotting with the indicated antibodies.
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Figure 7. Treatment of the 11-26 PDX Model Harboring Somatic BRCA1 R1443* Mutation
(A) Mice bearing xenografts were treated with vehicle or veliparib (n = 5/group). (Left) After 15 days, mice were sacrificed and tumors subjected to immuno-
fluorescence for RAD51 and g-H2AX foci. (Right) Quantification of g-H2AX-positive cells with more than five RAD51 foci. The p value is non-significant.
(B) Mice bearing xenografts were treatedwith vehicle or dinaciclib for two doses over 5 days (n = 3/group), after whichmicewere sacrificed and tumors stained for
RAD51. p = 0.059. Scale bar, 100 mm.
(C) Mice bearing xenografts were treated with vehicle (n = 3), dinaciclib (n = 7), veliparib (n = 4), or the combination (n = 10), demonstrating long-term growth
control with veliparib and sustained tumor regressions with combination treatment. After 2 months of treatment (day 61), *p < 0.001 for combination treatment
versus either monotherapy. All data in (A)–(C) are reported as the mean ± SEM.
(D) Waterfall plot demonstrating % change in tumor volume at the time of sacrifice for individual mice in the four treatment groups.
(E) Representative end-of-experiment histology (H&E) and g-H2AX staining of tumors isolated from mice in the four treatment groups. Scale bar, 100 mm.
(F) Quantification of % nuclei staining positively for g-H2AX at end of experiment (*p < 0.05 for combination versus control treatment). Data are reported as the
mean ± SD from a minimum of four xenografts/group.strategy may be effective even when the precise mechanism of
HR restoration is unknown. In the PDX model of acquired PARP
inhibitor resistance (12-58), aBRCA2 reversionwasnotdetected,
and theevents underlyingPARP inhibitor andplatinum resistance2378 Cell Reports 17, 2367–2381, November 22, 2016are under further investigation. Nonetheless, tumor growth inhibi-
tion was imposed by combined dinaciclib and PARP inhibition.
Hypomorphic BRCA1 proteins may account for some in-
stances of de novo PARP inhibitor resistance, illustrated by
mutations arising in exon 11 of the BRCA1 reading frame.
Consequently, BRCA1 D11b-expressing SUM149PT cells
exhibit primary PARP inhibitor resistance that may be reversed
by siRNA- or CDK12 inhibitor-mediated depletion of the hypo-
morphic protein or other components of the BRCA1-PALB2-
BRCA2 axis. In a second BRCA1-mutated cell line, HCC1937
(BRCA1 5382insC), PARP inhibitor resistance is BRCA1 inde-
pendent, possibly related to a compensatory role for RAD52
(Lok et al., 2013). HCC1937 cells continue to be dependent on
remaining components of the BRCA1-PALB2-BRCA2 axis,
allowing them to be similarly sensitized to PARP inhibition by
dinaciclib treatment. Additionally, the existence and clinical sig-
nificance of residual HR in tumors arising in PARP-inhibitor-naive
BRCA carriers has remained unknown. Here, we show evidence
of residual HR in the clinical course of a 185delAG BRCA1 car-
rier, whose tumor was resistant to olaparib, but sensitized with
dinaciclib.
Despite exhibiting PARP inhibitor resistance, SUM149PT and
HCC1937 cells, as well as the PDX 127 model, demonstrated
sensitivity to cisplatin. The retention of residual HR in these
models is not adequate to confer FA pathway proficiency, which
is required for the repair of damage induced by DNA crosslinking
agents. These results further emphasize that PARP inhibitor and
platinum sensitivity are not always concordant (Bunting et al.,
2012), and provide additional evidence for the importance of
platinum agents in BRCA-mutated TNBC.
Lastly, our work suggests that combined CDK12 and PARP in-
hibition is applicable to BRCA-deficient breast cancers that are
PARP inhibitor susceptible. Regressions in such tumors are
rarely complete, and in some cases are short-lived. In the
K14cre;BRCA1F/F;p53F/F genetically engineered mouse model
challenged with PARP inhibitor monotherapy, not all tumors
regress, with some demonstrating stable disease (Rottenberg
et al., 2008). Similarly, in sensitive BRCA-mutated TNBC PDX
models, outcomes frequently demonstrate stable tumor growth
inhibition or minor regression, without complete tumor response
(Juvekar et al., 2012). Therefore, the 11-26 PDX model derived
from a patient with early-stage TNBC harboring somatic
BRCA1 mutation is representative of PARP-inhibitor-sensitive
breast cancers and demonstrated prolonged tumor growth inhi-
bition with veliparibmonotherapy. The addition of dinaciclib con-
verted the outcome to sustained regression in all of the mice
treated, with only minimal residual disease evident on analysis
of end-of-treatment histology.
Although dinaciclib inhibits several cell cycle and transcrip-
tional CDKs, the modest effects on cell cycle progression
coupled with the transcriptional profile suggest that the pheno-
type we observed in tumor cells is primarily driven by inhibition
of CDK12. The highly potent CDK12 inhibitory activity in
biochemical assays distinguishes dinaciclib from all other CDK
inhibitors tested that target CDK family members to varying de-
grees (Bo¨sken et al., 2014). These results have implications
for the future development of dinaciclib and suggest that combi-
natorial strategies including PARP inhibitors or other DNA-
damaging agents should be prioritized.
An important requisite of any HR targeting strategy for PARP
inhibitor sensitization is selectivity for tumor cells. Dinaciclib-
mediated inhibition of cell cycle CDKs appears to arrest mam-mary epithelial cells in G2/M to a greater degree than TNBC cells.
This is expected to impede PARP-inhibitor-mediated cell death
that occurs in S phase, affording a favorable therapeutic index.
Further work will be required to determine whether concomitant
cell cycle CDK inhibition is necessary for the tolerability of com-
bined CDK12 and PARP inhibition. It is also possible that cells
with inherent genomic instability may be highly dependent on
CDK12-directed transcription to accomplish necessary repair,
and therefore particularly vulnerable to reduced CDK12 activity
in concert with PARP inhibition, whereas genetically stable
non-transformed cells may require only low rates of transcription
of such genes and are thus able to tolerate the degree of sup-
pression achieved by reversible kinase inhibition. Whatever the
precise mechanism, prolonged exposure to combined dinaciclib
and veliparib had no apparent toxicity to normal mouse organs,
while achieving profound tumor regression in the 11-26 model.
In summary, dinaciclib is a potent inhibitor of CDK12 that
effectively sensitizes BRCA wild-type and mutated models of
TNBC to PARP inhibition, overcoming primary and acquired
resistance. A phase 1 trial of dinaciclib and veliparib is currently
in progress (NCT01434316). Once recommended phase 2 doses
of the agents are established, the trial will enroll expansion co-




Dinaciclib, veliparib, and olaparib were provided by the National Cancer Insti-
tute (NCI) Division of Cancer Treatment and Diagnosis (DCTD) or purchased
from Selleck Chemicals. Flavopiridol and hydroxyurea were purchased from
Enzo Life Sciences and Sigma-Aldrich, respectively.
In Vitro Kinase Assays
Kinase reactions were carried out using recombinant full-length human CDK9
(1–372) and Cyclin T1 (1–272), and human CDK12 (696–1082) and Cyclin K
(1–267), as previously described (Bo¨sken et al., 2014). Measurements were
performed in triplicate.
Cell Lines and Cell Viability Assays
Cell lines were obtained from the American Type Culture Collection. For
viability assays, cells were seeded at 500–5,000/well on 96-well plates,
cultured in the presence of drugs or vehicle for 7 days, and assessed by
CellTiter-Glo (Promega). IC50 values, determined in the absence or presence
of dinaciclib, represent veliparib concentrations at which viability was reduced
by 50% of vehicle-treated cells. Cells treated with control siRNAs or those
targeting BRCA1, BRCA2, or PALB2 were replated in media containing
vehicle or veliparib, and viability was determined after 7 days. Mean viability
relative to vehicle-treated cells was calculated from a minimum of three
experiments.
Western Blotting
Western blotting was performed with antibodies recognizing BRCA1 (OP-92;
EMD Millipore), BRCA2 (OP-95; EMD Millipore), RAD51 (H-92; Santa Cruz
Biotechnology), FANCD2 (NB100-182; Novus Biologicals), g-H2AX [pS139]
(JBW301; EMD Millipore), histone H3 (AB1791; Abcam), CTD [pSer2] (3E10;
EMD Millipore), CTD [pSer5] (3E8; EMD Millipore), and total CTD (8WG16;
Abcam).
Gene Expression Array Analysis
MDA-MB-231 cells were treated in triplicate with either vehicle or dinaciclib for
12 hr, and RNA was collected using TRIzol and QIAGEN RNeasy mini kit.
Changes in transcription were measured using the Affymetrix HG-U133A2Cell Reports 17, 2367–2381, November 22, 2016 2379
array platform. Genes statistically significantly downregulated in response to
dinaciclib were imported into Ingenuity Pathway Analysis (IPA) software, and
networks of these focused genes were built based on the Ingenuity Knowledge
Base.
Establishment and Treatment of Patient-Derived Xenografts
Patient consent for tumor implantation in nude mice was obtained under pro-
tocols approved by the IRB of the Dana-Farber/Harvard Cancer Center and
the Clinical Investigation Ethical Committee of the Vall D’Hebron University
Hospital. Mice were maintained in accordance with local guidelines and ther-
apeutic interventions approved by the Animal Care and Use Committees of
Dana-Farber Cancer Institute, Vall D’Hebron Institute of Oncology and the
Garvan Institute of Medical Research. TNBC samples were implanted into
the cleared fourth mammary fat pads of NOD-SCID-IL2Rgc–/– mice (Jackson
Laboratories) or were subcutaneously implanted in female HsdCpb:NMRI-
Foxn1numice (Harlan Laboratories) at 6 weeks of age. For the PDX 127 model,
animals were supplemented with 1 mmol/L estradiol (Sigma) in the drinking wa-
ter. After engraftment, tumor tissue was re-implanted into recipient mice,
which were randomized when volumes reached 100–300 mm3 to receive
vehicle, veliparib or olaparib, dinaciclib, or the combination of PARP inhibitor
and dinaciclib, with 5–10 mice/group. Animals were treated by oral gavage
with veliparib (50 mg/kg twice daily) (Donawho et al., 2007), olaparib (50 mg/
kg 6 days/week) (Juvekar et al., 2012), or with intraperitoneal dinaciclib
(8 mg/kg 6 days/week for PDX 127 or 30 mg/kg twice weekly for PDXs 11-
26 and 12-58) (Parry et al., 2010). Cisplatin was administered at 6 mg/kg
(PDX 127) or 8 mg/kg (PDX 12-58) (Rottenberg et al., 2007). Caliper measure-
ments were used to determine tumor volumes as length 3 width2. Tumor vol-
umes are plotted as mean ± SEM.
Immunofluorescence and Focal Microscopy
Primary antibodies recognizing BRCA1, RAD51, and g-H2AX [pS139] were
followed by secondary antibodies conjugated to fluorescein isothiocyanate
(FITC) or Texas red (Jackson ImmunoResearch Laboratories). Confocal
immunofluorescence images were acquired using Andor iQ software. For
metaphase spreads, cells were exposed for 2 hr to Colcemid, harvested,
and stained with Wright’s stain. Fifty metaphase spreads were scored for
aberrations, captured using CytoVision software (Applied Imaging).
Histological and Immunohistochemical Staining
Formalin-fixed, paraffin-embedded sections of harvested xenografts were
stained with H&E or antibodies against g-H2AX [pS139] or RAD51. At least
three xenografts, each with at least five 403 fields, were manually scored
or quantified by Aperio image analysis for each treatment. For toxicology as-
sessments, mouse organs from vehicle- or combination-treated mice were
harvested, formalin fixed, H&E stained, and evaluated histologically, as well
as for g-H2AX staining.
Statistical Analysis
A p value <0.05 was considered statistically significant in two-tailed, unpaired
Student’s t tests.
ACCESSION NUMBERS
The accession number for the gene expression analysis in vehicle- and dina-
ciclib-treated MDA-MB-231 cells is NCBI GEO: GSE88822.
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